KDR and sarcoma: We used DC101, an anti-VEGFR-2 antibody, to block the primary receptor of VEGF-A, metronomic doxorubicin to block HIF-1α binding to DNA, and the hypoxia-activated chemotherapeutic evofosfamide (a.k.a. multimodal therapy) in the LSL-KrasG12D/+/Trp53fl/fl genetically engineered mouse model of sarcoma, which we have previously described [35].